# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021069
Filing Date
2024-05-07
Accepted
2024-05-07 16:02:30
Documents
81
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | bcrx-20240331.htm iXBRL | 10-Q | 1293523
2 | EX-31.1 | bcrx-20240331xexx311.htm | EX-31.1 | 9615
3 | EX-31.2 | bcrx-20240331xexx312.htm | EX-31.2 | 9589
4 | EX-32.1 | bcrx-20240331xexx321.htm | EX-32.1 | 4662
5 | EX-32.2 | bcrx-20240331xexx322.htm | EX-32.2 | 4636
| Complete submission text file | 0001628280-24-021069.txt |  | 7414985

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | bcrx-20240331.xsd | EX-101.SCH | 59388
7 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | bcrx-20240331_cal.xml | EX-101.CAL | 62622
8 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | bcrx-20240331_def.xml | EX-101.DEF | 245960
9 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | bcrx-20240331_lab.xml | EX-101.LAB | 693809
10 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | bcrx-20240331_pre.xml | EX-101.PRE | 472475
84 | EXTRACTED XBRL INSTANCE DOCUMENT | bcrx-20240331_htm.xml | XML | 1029130

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 24921671
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)